Liquid biopsy mutation panel for non-small cell lung cancer: analytical validation and clinical concordance

Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review

(2018) Jason D. Merker et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

(2018) Alexander Drilon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Dabrafenib and Trametinib for the Treatment of Metastatic Non‐Small Cell Lung Cancers HarboringBRAF V600EMutations

(2018) Lauretta Odogwu et al.   ONCOLOGIST

Concordance between Comprehensive Cancer Genome Profiling in Plasma and Tumor Specimens

(2017) Judith N. Müller et al.   Journal of Thoracic Oncology

Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

(2016) Ryo Ko et al.   BMC CANCER

ctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS Study

(2016) Martin Reck et al.   Journal of Thoracic Oncology

Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer†

(2015) C. Lim et al.   ANNALS OF ONCOLOGY

First-line erlotinib versus gemcitabine/cisplatin in patients with advancedEGFRmutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

(2015) Y.-L. Wu et al.   ANNALS OF ONCOLOGY

FDA Approval: Ceritinib for the Treatment of Metastatic Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

(2015) S. Khozin et al.   CLINICAL CANCER RESEARCH

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy

(2015) T. Mok et al.   CLINICAL CANCER RESEARCH

Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA

(2015) J. Uchida et al.   CLINICAL CHEMISTRY

Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients

(2015) Antonio Marchetti et al.   Journal of Thoracic Oncology

Dynamic Plasma EGFR Mutation Status as a Predictor of EGFR-TKI Efficacy in Patients with EGFR-Mutant Lung Adenocarcinoma

(2015) Jeng-Sen Tseng et al.   Journal of Thoracic Oncology

Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer

(2015) Chen Mao et al.   MEDICINE

Timeliness of Diagnosing Lung Cancer

(2015) Akash Verma et al.   MEDICINE

Identification of major factors associated with failed clinical molecular oncology testing performed by next generation sequencing (NGS)

(2015) Hussam Al-Kateb et al.   Molecular Oncology

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

(2015) Giulia Siravegna et al.   NATURE MEDICINE

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

(2015) Kenneth S Thress et al.   NATURE MEDICINE

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

(2015) Pasi A. Jänne et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association ofEGFRL858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

(2015) Niki Karachaliou et al.   JAMA Oncology

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

(2014) Britta Weber et al.   BMC CANCER

Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer

(2014) Kate McKeage   DRUGS

Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status

(2014) Jean-Yves Douillard et al.   Journal of Thoracic Oncology

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients

(2014) J.L. Kuiper et al.   LUNG CANCER

An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage

(2014) Aaron M Newman et al.   NATURE MEDICINE

Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

(2014) Alice T. Shaw et al.   NEW ENGLAND JOURNAL OF MEDICINE

FDA Approval Summary: Crizotinib for the Treatment of Metastatic Non-Small Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements

(2014) D. Kazandjian et al.   ONCOLOGIST

U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

(2014) Sean Khozin et al.   ONCOLOGIST

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution

(2014) E. C. de Bruin et al.   SCIENCE

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

(2014) C. Bettegowda et al.   Science Translational Medicine

Afatinib: First Global Approval

(2013) Rosselle T. Dungo et al.   DRUGS

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer

(2011) Koichi Goto et al.   Journal of Thoracic Oncology